Why Cardiol Therapeutics (CRDL) Stock Is Down 20% Today
Why Cardiol Therapeutics (CRDL) Stock Is Down 20% Today
Cardiol Therapeutics Inc (NASDAQ:CRDL) shares are trading lower by 18.4% to $1.60 Wednesday morning after the company announced a $13.5 million public offering of 8,437,500 common shares priced at $1.60 per unit.
週三上午，Cardiol Therapeutics Inc（納斯達克股票代碼：CRDL）股價下跌18.4％，至1.60美元，此前該公司宣佈以每單位1.60美元的價格公開發行1,350萬美元的8,437,500股普通股。
What Else: Cardiol Therapeutics says the gross proceeds will be approximately $13.5 million before underwriting discounts, commissions and other related expenses.
還有什麼：Cardiol Therapeutics表示，在承保折扣、佣金和其他相關費用之前，總收益約爲1,350萬美元。
The company plans to use the net proceeds from the offering to advance the clinical development of its lead drug candidate, CardiolRx, which is being investigated for the treatment of recurrent pericarditis, a cardiovascular condition. Additionally, the funds will support general administrative expenses, working capital and other corporate purposes.
該公司計劃將此次發行的淨收益用於推進其主要候選藥物CardioLRX的臨床開發，該藥物正在研究用於治療複發性心包炎（一種心血管疾病）。此外，這些資金將用於支持一般管理費用、營運資金和其他公司用途。
Canaccord Genuity is serving as the sole bookrunner for the offering, overseeing the distribution of the shares.
Canaccord Genuity是本次發行的唯一賬簿管理人，負責監督股票的分配。
Read Also: Google Cries Foul As DOJ Moves To Break Up Search Giant, Calls Recommendations 'Radical' As Antitrust Ruling Aims To Limit Its Search Market Monopoly
另請閱讀：隨着司法部開始解散搜索巨頭，谷歌大聲疾呼 「激進」，因爲反壟斷裁決旨在限制其搜索市場的壟斷
Should I Sell My CRDL Stock?
我應該賣出我的 CRDL 股票嗎？
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
是賣出還是持有股票在很大程度上取決於投資者的策略和風險承受能力。波段交易者可能會出售表現跑贏大盤的股票以鎖定資本收益，而長期投資者可能會在股價進一步增長的預期下渡過難關。
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
同樣，願意最大限度地減少損失的交易者可能會賣出下跌一定百分比的股票，而長期投資者則可能將其視爲以折扣價購買更多股票的機會。
Shares of Cardiol Therapeutics have gained 68.09% year to date. This compares to the average annual return of -16.86%, meaning the stock has outperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.
迄今爲止，Cardiol Therapeutics的股價已上漲68.09％。相比之下，平均年回報率爲-16.86％，這意味着該股的表現超過了歷史平均水平。投資者可以將股票的走勢與其歷史表現進行比較，以評估這是正常走勢還是潛在的交易機會。
For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.
如需分析工具、圖表數據和獲取獨家股票新聞，請查看 Benzinga PRO。免費試用。
CRDL has a 52-week high of $3.12 and a 52-week low of $0.66.
CRDL的52周高點爲3.12美元，52周低點爲0.66美元。
